ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect and efficacy of ONO-4538.
Malignant Solid Tumor
BIOLOGICAL: ONO-4538
Cmax at Single Dose, day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation|AUClast at Single Dose, day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation|T1/2 at Single Dose, day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation|Ceoi at Multiple Doses, Ceoiï¼šSerum concentrations immediately after the end of continuous administration, day 15
Best Overall Response, Response Evaluation Criteria In Solid Tumors Criteria (ver 1.0) was used for this Outcome Measure.

Please see the reference for the detailed description. Therasse, Arbuck et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16., up to study completion, every 4 weeks in principle
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect and efficacy of ONO-4538.